Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer

British Journal of Cancer

Volumn 92, Issue 2, 2005, Pages 376-381

  Edwards, S ^a   Campbell, C ^b   Flohr, P ^a   Shipley, J ^a   Giddings, I ^a   Te Poele, R ^a   Dodson, A ^c   Foster, C ^c   Clark, J ^a   Jhavar, S ^a   Kovacs, G ^d   Cooper, C S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d University Surgical Hospital   (Germany)

Author keywords

Expression; HOXB13; Microarray; Prostate

Indexed keywords

COMPLEMENTARY DNA; FATTY ACID SYNTHASE; HOMEOBOX PROTEIN HOX B13; HOMEOBOX PROTEIN NKX 3.1; HOMEODOMAIN PROTEIN; KALLIKREIN 2 PRECURSOR PROTEIN; NERVE CELL ADHESION MOLECULE; NEURAL CELL ADHESION MOLECULE 2 PRECURSOR PROTEIN; NUCLEAR PROTEIN; PROSTATE PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTEIN; PROTEIN PRECURSOR; RETINOL DEHYDROGENASE; RETINOL DEHYDROGENASE 11; SCLEROPROTEIN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 2 PROTEIN; SMALL NUCLEAR PROTEIN PRAC; SPONDIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL TYPE; CONTROLLED STUDY; DATA BASE; DECISION MAKING; DISEASE MARKER; DNA DETERMINATION; DNA LIBRARY; DNA MICROARRAY; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERIAL ANALYSIS OF GENE EXPRESSION; TISSUE SPECIFICITY; UBIQUITINATION;

CELL LINE, TUMOR; DNA, COMPLEMENTARY; HOMEODOMAIN PROTEINS; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 20044385928     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602261     Document Type: Article

References (44)

1. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J (2002) Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22: 1495-1503
2. Ben Dor A, Bruhn L, Friedman N, Nachman I, Schummer M, Yakhini Z (2000) Tissue classification with gene expression profiles. J Comput Biol 7: 559-583
3. Berthon P, Cussenot O, Hopwood L, Le Duc A, Maitland NJ (1995) Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumourigenic cell lines. Int J Oncol 6: 333-343
4. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM (1999) Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13: 966-977
5. Bieberich CJ, Fujita K, He WW, Jay G (1996) Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 271: 31779-31782
6. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF, Gardiner RA (2002) Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 100: 228-237
7. Clark J, Edwards S, John M, Flohr P, Gordon T, Maillard K, Giddings I, Brown C, Bagherzadeh A, Campbell C, Shipley J, Wooster R, Cooper CS (2002) Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer 34: 104-114
8. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG (1997) Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49: 857-862
9. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826
10. Economides KD, Capecchi MR (2003) Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130: 2061-2069
11. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M, Grone HJ (2002) Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160: 2169-2180
12. Gelmann EP, Bowen C, Bubendorf L (2003) Expression of NKX3.1 in normal and malignant tissues. Prostate 55: 111-117
13. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH (2004) HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 64: 3046-3051
14. Kondo T, Zakany J, Innis JW, Duboule D (1997) Of fingers, toes and penises. Nature 390: 29
15. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F (2002) Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 277: 36689-36696
16. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, Dunn RL, Chinnaiyan AM, Rubin MA (2002) Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 161: 841-848
17. Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM (2003) Prostate cancer biomarkers: a current perspective. Expert Rev Mol Diagn 3: 459-470
18. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506
19. Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, True LD, Hood L, Nelson PS (2001) Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Res 61: 1611-1618
20. Liu XF, Olsson P, Wolfgang CD, Bera TK, Duray P, Lee B, Pastan I (2001) PRAC: a novel small nuclear protein that is specifically expressed in human prostate and colon. Prostate 47: 125-131
21. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB (2001) Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683-4688
22. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M (2002) Gene expression analysis of prostate cancers. Mol Carcinogen 33: 25-35
23. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Baus U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616
24. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696
25. Manda R, Kohno T, Matsuno Y, Takenoshita S, Kuwano H, Yokota J (1999) Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. Genomics 61: 5-14
26. Olsson P, Motegi A, Bera TK, Lee B, Pastan I (2003) PRAC2: a new gene expressed in human prostate and prostate cancer. Prostate 56: 123-130
27. Paoloni-Giacobino A, Chen H, Antonarakis SE (1997) Cloning of a novel human neural cell adhesion molecule gene (NCAM2) that maps to chromosome region 21q2J and is potentially involved in Down syndrome. Genomics 43: 43-51
28. Podlasek CA, Clemens JQ, Bushman W (1999) Hoxa-13 gene mutation results in abnormal seminal vesicle and prostate development. J Urol 161: 1655-1661
29. Podlasek CA, Duboule D, Bushman W (1997) Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn 208: 454-465
30. Price D (1963) Comparative aspects of development and structure in the prostate. Natl Cancer Inst Monogr 12: 1-27
31. Rees DG (2001) Essential Statistics. Boca Raton, Florida: Chapman & Hall
32. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM (2002) Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433
33. Sciavolino PJ, Abrams EW, Yang L, Austenberg LP, Shen MM, Abate-Shen C (1997) Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Dev Dyn 209: 127-138
34. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209
35. Sreenath T, Orosz A, Fujita K, Bieberich CJ (1999) Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 41: 203-207
36. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S (2002) HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 62: 6812-6816
37. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z (2001) Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 166: 2171-2177
38. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916
39. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629
40. Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P (1997) Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development 124: 4781-4791
41. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson Jr HF, Hampton GM (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978
42. Wilkinson M (1988) A rapid and convenient method for isolation of nuclear, cytoplasmic and total cellular RNA. Nucleic Acids Res 16: 10934
43. Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, Filho AM, Nolasco M, Badaro R, Reed SG (2001) Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 61: 1563-1568
44. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, Soppett D, Srivastava S (2000) PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 60: 6568-6572